NDC product
LAMIVUDINE and ZIDOVUDINE
NDC 31722-506 · Camber Pharmaceuticals, Inc.
Key facts
| Product NDC | 31722-506 |
|---|---|
| Proprietary name | LAMIVUDINE and ZIDOVUDINE |
| Nonproprietary name | LAMIVUDINE and ZIDOVUDINE |
| Substances | LAMIVUDINE, ZIDOVUDINE |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Camber Pharmaceuticals, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA079124 |
| Pharmacologic classes | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| Marketing start | Sep 18, 2015 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: